Legend Biotech (LEGN) Cash & Equivalents (2019 - 2025)

Legend Biotech has reported Cash & Equivalents for 7 years, with the latest figure at $286.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents changed 0.0% year-over-year to $286.7 million; the trailing twelve-month figure through Dec 2025 stood at $286.7 million (changed 0.0% YoY), and the FY2025 full-year result was $286.7 million, changed 0.0% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $286.7 million, up from $278.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.3 billion in Q4 2023, with the low at $201.3 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $594.6 million across 5 years, with a median of $473.7 million in 2021.
• Annual changes were most pronounced in 2021 — Cash & Equivalents soared 485.64% — and 2024, when it tumbled 83.68%.
• Legend Biotech's Cash & Equivalents stood at $688.9 million in 2021, then advanced by 14.09% to $786.0 million in 2022, then jumped by 62.55% to $1.3 billion in 2023, then tumbled by 77.56% to $286.7 million in 2024, then changed by 0.0% to $286.7 million in 2025.
• The last three Cash & Equivalents figures came in at $286.7 million (Q4 2025), $278.9 million (Q3 2025), and $266.6 million (Q2 2025), per Business Quant data.